CTOs on the Move

Innovative Medical Device Solutions (IMDS)

www.imds.net

 
IMDS (Innovative Medical Device Solutions) provides comprehensive product development and supply chain management solutions for medical device companies, with a focus on the orthopedic industry. IMDS is the integration of the following companies: Leis
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.imds.net
  • 13600 Heritage Pkwy Ste 170
    Fort Worth, TX USA 76177
  • Phone: 877.583.0677

Executives

Name Title Contact Details

Similar Companies

Emergency Ambulance Service

Emergency Ambulance Service is a Brea, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Baker Eye Institute

Baker Eye Institute is a Clinton, AR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PlayMaker Health

PlayMaker Health`s post-acute software transforms provider claims into actionable business intelligence. Integrating within existing industry workflows, the platform, and mobile-first CRM unify market and sales performance data, delivering the actionable analytics and business intelligence post-acute providers need to accelerate growth and expand competitive market share.

Mediflex Surgical Products

Mediflex Surgical Products is a Pittsboro, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bionor Pharma

Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.